1.
High Uptake of Respiratory Syncitial Virus Prevention for Neonates in a Military Treatment Facility.
J Pediatr
; 273: 114144, 2024 Jun 12.
Article
in English
| MEDLINE
| ID: mdl-38876155
ABSTRACT
We investigated the uptake of nirsevimab for infants and the bivalent respiratory syncytial virus prefusion F (RSVPreF) vaccine for pregnant persons as measures for RSV prevention during an infant's birth hospitalization in a military treatment facility. We found >85% uptake between October 2023 to February 2024. These data may aid health systems plan for future RSV seasons.
